Biosimilars

Explore approved biosimilar medicines

# Medicine Status Active Substance Therapeutic Area Developer Published Date
51 Kefdensis Authorised denosumab Bone Resorption;Osteoporosis;Osteoporosis, Postmenopausal Stada Arzneimittel AG 19-09-2025
52 Afqlir Authorised aflibercept Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion Sandoz GmbH 20-09-2024
53 Nivestim Authorised filgrastim Hematopoietic Stem Cell Transplantation;Cancer Pfizer Europe MA EEIG 23-08-2018
54 Retacrit Authorised epoetin zeta Anemia;Blood Transfusion, Autologous;Kidney Failure, Chronic;Cancer Pfizer Europe MA EEIG 03-08-2018
55 Bysumlog Opinion insulin lispro Diabetes Mellitus Gan & Lee Pharmaceuticals Europe GmbH 27-02-2026
56 Conexxence Authorised denosumab Osteoporosis;Osteoporosis, Postmenopausal;Bone Resorption Fresenius Kabi Deutschland GmbH 23-05-2025
57 Yesafili Authorised aflibercept Macular Edema;Retinal Vein Occlusion;Diabetic Retinopathy;Myopia, Degenerative;Diabetes Complications Biosimilar Collaborations Ireland Limited 17-07-2023
58 Byooviz Authorised ranibizumab Wet Macular Degeneration;Macular Edema;Diabetic Retinopathy;Myopia, Degenerative Samsung Bioepis NL B.V. 23-06-2021
59 Gotenfia Authorised golimumab Arthritis, Rheumatoid;Arthritis, Juvenile;Arthritis, Psoriatic;Axial Spondyloarthritis;Non-Radiographic Axial Spondyloarthritis;Colitis, Ulcerative Stada Arzneimittel AG 12-12-2025
60 Vivlipeg Authorised pegfilgrastim Neutropenia;Febrile Neutropenia;Chemotherapy-Induced Febrile Neutropenia;Cancer Biosimilar Collaborations Ireland Limited 02-10-2025

Get in Touch

Ready to transform your strategic intelligence? Let's talk

Subscribe to Our Newsletter

Get latest pharmaceutical insights, blogs, and strategic updates directly in your inbox.